Hnscc clinical trials

Explore recruiting hnscc clinical trials.

Recruiting hnscc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hnscc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Spain, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Spain, Netherlands, Belgium, Poland, France, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

AFAN trial. Phase Ib/II study to investigate the safety and efficacy of Afatinib when administered as therapy in Fanconi anemia patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Phase 3 study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma.

Norway, Czechia, Portugal, Greece, Spain, Germany +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TIRACAN; Open label phase 2 basket trial with Atezolizumab and Tiragolumab in solid tumors

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Hnscc trials by city

Hnscc in Toronto Hnscc in Vancouver Hnscc in Montreal Hnscc in Calgary Hnscc in Edmonton Hnscc in Ottawa Hnscc in Winnipeg Hnscc in Quebec City Hnscc in Hamilton Hnscc in Kitchener Hnscc in London Hnscc in Halifax Hnscc in New York Hnscc in Los Angeles Hnscc in Chicago Hnscc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease